NEWSROOM Press Releases

    Year
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study

    October 28, 2013

    PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.

    Biodesix Announces Publication of Seminal PROSE Study in THE LANCET ONCOLOGY

    May 14, 2014

    Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)

    Biodesix Announces Results in Phase III Lung Cancer Diagnostic Study; First Prospective Biomarker-Stratified Validation Study in Oncology

    June 3, 2013

    Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.